1/18
06:11 am
cntx
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/16
04:05 pm
cntx
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/22
08:02 am
cntx
Context Therapeutics (NASDAQ:CNTX) is now covered by analysts at Jones Trading. They set a "buy" rating and a $7.00 price target on the stock.
Medium
Report
Context Therapeutics (NASDAQ:CNTX) is now covered by analysts at Jones Trading. They set a "buy" rating and a $7.00 price target on the stock.
11/22
02:11 am
cntx
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
Low
Report
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
11/22
02:11 am
cntx
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
Low
Report
Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at
Wall Stre
11/7
07:30 am
cntx
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
Low
Report
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
11/6
09:39 am
cntx
Context Therapeutics GAAP EPS of -$0.10 misses by $0.01 [Seeking Alpha]
Low
Report
Context Therapeutics GAAP EPS of -$0.10 misses by $0.01 [Seeking Alpha]
11/6
08:40 am
cntx
Context Therapeutics (NASDAQ:CNTX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Medium
Report
Context Therapeutics (NASDAQ:CNTX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
11/6
08:10 am
cntx
Context Therapeutics (NASDAQ:CNTX) had its price target raised by analysts at HC Wainwright from $4.00 to $5.00. They now have a "buy" rating on the stock.
High
Report
Context Therapeutics (NASDAQ:CNTX) had its price target raised by analysts at HC Wainwright from $4.00 to $5.00. They now have a "buy" rating on the stock.
11/5
04:15 pm
cntx
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Medium
Report
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
10/28
07:30 am
cntx
Context Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Context Therapeutics to Participate in Upcoming Investor Conferences